GEN Exclusives

More »

GEN News Highlights

More »
Mar 25, 2009

Daiichi Sankyo Obtains Rights to Gene Bridges’ Recombineering Technology

  • Daiichi Sankyo has inked a commercial license agreement for the use of the Red/ET recombination technology from Gene Bridges. The Red/ET recombination technology is a method for generating targeting vectors or modifying E. coli chromosomes.
    According to Gene Bridges, recombineering with Red/ET allows cloning, subcloning, and modification of DNA at any chosen position. It permits precise engineering of DNA molecules of any size, including large ones such as BACs or the E.coli chromosome.



GEN Jobs powered by connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
More »

Be sure to take the GEN Poll

Disclosing Clinical Trial Data

Do you believe that conducting performance audits for new drugs will incentivize pharma firms to become more transparent?

More »